Eli Lilly buys psychedelics biotech AtaiBeckley for $2.8B

Eli Lilly is acquiring AtaiBeckley, a biotech focused on psychedelic therapies, for $2.8 billion up front. This move significantly expands Lilly's neuroscience pipeline, specifically targeting mental health conditions. It signals a major pharmaceutical player betting big on psychedelics for depression and other disorders.